Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 19/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 19/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 19/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 19/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 19/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 19/20 | 1.00 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.73 |
| ▸ | GSAP | A4D1B5 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393672 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30014271 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14876879 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3046688 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18425107 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4990943 | 0.92 | PSEN1 (0.86) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4422325 | 0.89 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24061930 | 0.85 | PSEN1 (0.73) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL33171 | 0.84 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13749875 | 0.84 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230405124-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF IMMUNE SYSTEM DYSFUNCTION | Oncotracker, Inc. | 2023-12-21 | — | — | US | claimed |
| EP-3662909-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF IMMUNE SYSTEM DYSFUNCTION | Oncotracker, Inc. (US) | 2020-06-10 | — | — | EP | claimed |
| US-20180214553-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF IMMUNE SYSTEM DYSFUNCTION | INSTITUTE FOR MYELOMA & BONE CANCER RESEARCH | 2018-08-02 | — | — | US | claimed |
| US-20150359799-A1 | METHODS OF TREATING, PREVENTING AND DIAGNOSING LEUKEMIA AND OTHER BLOOD DISEASES AND DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-17 | — | — | US | claimed |
| WO-2012050370-A2 | COMPOSITION FOR PREVENTING OR TREATING RHEUMATOID ARTHRITIS CONTAINING A GAMMA SECRETASE INHIBITOR AS AN ACTIVE INGREDIENT | 성균관대학교산학협력단 (KR) | 2012-04-19 | — | — | WO | claimed |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2026-05-12 | — | — | US | disclosed |
| EP-3458076-B1 | HUMAN AIRWAY STEM CELLS IN LUNG EPITHELIAL ENGINEERING | MASSACHUSETTS GEN HOSPITAL (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4691479-A2 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | NOVARTIS AG (CH) | 2026-02-05 | — | — | US | disclosed |
| EP-4194548-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-09-23 | — | — | US | disclosed |
| EP-3970725-B1 | A GAMMA SECRETASE INHIBITOR FOR TREATING HEARING LOSS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2025-08-20 | — | — | EP | disclosed |
| WO-2012129393-A1 | ASSAY FOR SCREENING COMPOUNDS THAT SELECTIVELY DECREASE THE NUMBER OF CANCER STEM CELLS | THE ROGOSIN INSTITUTE (US) | 2012-09-27 | — | — | WO | disclosed |
| WO-2011038300-A1 | CANCER STEM CELLS, KITS, AND METHODS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20100278789-A1 | METHODS OF GENERATING EXPANDED AND RE-DIFFERENTIATED ADULT ISLET BETA CELLS CAPABLE OF PRODUCING INSULIN | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2010-11-04 | — | — | US | disclosed |
| WO-2010104176-A1 | MEGA-PHOSPHOPROTEIN CLEAVAGE INHIBITOR | 味の素株式会社 (JP) | 2010-09-16 | — | — | WO | disclosed |
| US-20100222283-A1 | USE OF GAMMA SECRETASE INHIBITORS AND NOTCH PATHWAY INHIBITORS FOR TREATMENT AND PREVENTION OF RENAL DESEASE | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2010-09-02 | — | — | US | disclosed |
| US-20100093684-A1 | SYNERGISTIC INTERACTION OF NOTCH-1 INHIBITORS WITH GLUCOCORTICOIDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2009035522-A1 | USE OF GAMMA SECRETASE INHIBITORS AND NOTCH PATHWAY INHIBITORS FOR TREATMENT AND PREVENTION OF RENAL DISEASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008112249-A1 | SYNERGISTIC INTERACTION OF NOTCH-1 INHIBITORS WITH GLUCOCORTICOIDS | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | GSK3B, GSKIP, BACE1 | PSEN1 21/4885PSEN2 36/4885APH1B 78/4885 |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | BCL9, BRCA1, VCAM1 | PSEN1 529/4885PSEN2 884/4885APH1B 1103/4885 |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | CD2, CD40, CD22 | PSEN1 1744/4885PSEN2 2511/4885APH1B 2583/4885 |
| US-20100222283-A1 | USE OF GAMMA SECRETASE INHIBITORS AND NOTCH PATHWAY INHIBITORS FOR TREATMENT AND PREVENTION OF RENAL DESEASE | BACE1, GSAP, BACE2 | PSEN1 65/4885PSEN2 77/4885APH1B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.